Tag: Intellia Therapeutics

A significant regulatory roadblock has been removed for Intellia Therapeutics. The U.S. Food and Drug Administration (FDA) has lifted the ...

Intellia Therapeutics' stock is facing renewed pressure following a brief technical rally. While shares closed the previous week with a ...

Intellia Therapeutics finds itself in a challenging phase as regulatory delays for a key drug candidate trigger a wave of ...

Shares of genome-editing company Intellia Therapeutics closed the trading week in negative territory, continuing a period of pronounced weakness. The ...

Shares of Intellia Therapeutics are experiencing significant downward pressure, with the stock price declining 3.80% to $8.10 as investor sentiment ...

A significant shift in analyst sentiment is casting a shadow over Intellia Therapeutics, sending its stock downward and prompting investors ...

A severe clinical setback has struck Intellia Therapeutics, sending its stock value tumbling after the U.S. Food and Drug Administration ...

A dramatic reassessment is underway for Intellia Therapeutics, sending shockwaves through the biotech investment community. Market research firm Morningstar has ...

While market sentiment remains divided, a significant move by a major investment firm suggests growing institutional confidence in gene-editing specialist ...

A patient death in a key study has triggered a severe downturn for Intellia Therapeutics, with the gene-editing company's stock ...